达托霉素致嗜酸粒细胞性肺炎的文献分析

doi:10.19803/j.1672-8629.2022.07.13

中国药物警戒 ›› 2022, Vol. 19 ›› Issue (7): 757-761.
DOI: 10.19803/j.1672-8629.2022.07.13

达托霉素致嗜酸粒细胞性肺炎的文献分析

孙宝^1,4, 白延宁², 张媛媛³, 乔逸^4,*, 杨志福⁴, 王婧雯⁴, 文爱东⁴

¹西安医学院第二附属医院药剂科,陕西西安 710038;
²延安大学附属医院临床药学科,陕西延安 716000;
³陕西中医药大学第二附属医院药剂科,陕西咸阳 712030;
⁴空军军医大学西京医院药剂科,陕西西安 710032

收稿日期:2020-08-21 出版日期:2022-07-15 发布日期:2022-07-12
通讯作者: ^*乔逸,男,博士,副主任药师·硕导,临床药学与药事管理研究。E-mail：694305040@qq.com
作者简介:孙宝,男,硕士,药师,临床药学与药物代谢。
基金资助:
国家自然科学基金(81573549)

Literature review of eosinophilic pneumonia induced by daptomycin

SUN Bao^1,4, BAI Yanning², ZHANG Yuanyuan³, QIAO Yi^4,*, YANG Zhifu⁴, WANG Jingwen⁴, WEN Aidong⁴

¹Department of Pharmacy, the Second Affiliated Hospital of Xi'an Medical University, Xi'an Shaanxi 710038, China;
²Department of Clinical Pharmacy, Yan'an University Affiliated Hospital, Yan'an Shaanxi 716000, China;
³Department of Pharmacy, the Second Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang Shaanxi 712030, China;
⁴Department of Pharmacy, Xijing Hospital, Air Force Medical University, Xi'an Shaanxi 710032, China

Received:2020-08-21 Online:2022-07-15 Published:2022-07-12

摘要/Abstract

摘要： 目的探讨达托霉素致嗜酸粒细胞性肺炎（eosinophilic pneumonia, EP）的一般规律和特点,为临床合理用药提供参考。方法以关键词对2004年1月1日至2020年7月31日中国知网、万方数据、维普网、PubMed等数据库进行检索,按照患者一般情况、用药情况、药品不良反应（ADR）发生及转归等进行统计分析。结果共收集29篇文献,包含了51例达托霉素所致的嗜酸粒细胞性肺炎;男女比例为5.25∶1,老年组发生率最高,为54.91%（28/51）;发生时间在1~2周的最多,占27.45%（14/51）;临床表现主要为嗜酸粒细胞增多、呼吸困难、发热等。本研究结果表明达托霉素致嗜酸粒细胞性肺炎可能与剂量和年龄相关,而与性别、ADR史和合并用药无关。结论达托霉素致ADR表现多样,临床医师、临床药师、护士都应该重视达托霉素所致的ADR,提高合理用药,确保临床用药安全。

关键词: 达托霉素, 嗜酸粒细胞性肺炎, 药品不良反应, 文献分析

Abstract: Objective To explore the regularity and characteristics of daptomycin-induced adverse reactions, and to provide reference for clinical rational drug use. Methods Such databases as CNKI, Wanfang, VIP, and PubMed were searched for articles about daptomycin-induced ADR that had been published between January 1, 2004 and July 31, 2019. Data on conditions of patients, medications, occurrence of ADR and prognosis was statistically analyzed. Results A total of 29 articles involving 51 cases of daptomycin-induced ADR-eosinophilic pneumonia-were included in this study. In these cases, the ratio of males to females was 5.25∶1. Most of the ADR occurred among elderly patients, accounting for 54.91% (28/51). 27.45% (14/51) of these ADR occurred within one to two weeks of medication. The main clinical manifestations were eosinophilia, dyspnea and febrile. The risk factors of eosinophilic pneumonia in patients might be related to age and dosage rather than to gender, the ADR history and combination of drugs. Conclusion Daptomycin-induced ADR vary, which deserve the attention of clinicians, clinical pharmacists and nurses so as to improve the rational use of drugs, and ensure the safety of medication.

Key words: daptomycin, eosinophilic pneumonia, adverse drug reaction, literature analysis

中图分类号:

R994.11

孙宝, 白延宁, 张媛媛, 乔逸, 杨志福, 王婧雯, 文爱东. 达托霉素致嗜酸粒细胞性肺炎的文献分析[J]. 中国药物警戒, 2022, 19(7): 757-761.

SUN Bao, BAI Yanning, ZHANG Yuanyuan, QIAO Yi, YANG Zhifu, WANG Jingwen, WEN Aidong. Literature review of eosinophilic pneumonia induced by daptomycin[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 757-761.

参考文献

[1] DEBONO M, BARNHART M, CARRELL CB, et al.A21978C, a complex of new acidic peptide antibiotics: isolation, chemistry, and mass spectral structure elucidation[J]. J Antibiot (Tokyo), 1987, 40(6): 761-777.
[2] MÜLLER A, WENZEL M, STRAHL H, et al. Daptomycin inhibits cell envelope synthesis by interfering with fluid membrane microdomains[J]. Proc Natl Acad Sci U S A, 2016, 113(45): E7077-E7086.
[3] COBB E, KIMBROUGH RC, NUGENT KM, et al.Organizing pneumonia and pulmonary eosinophilic infiltration associated with daptomycin[J]. Ann Pharmacother, 2007, 41(4): 696-701.
[4] HAYES D JR, ANSTEAD MI, KUHN RJ.Eosinophilic pneumonia induced by daptomycin[J]. J Infect, 2007, 54(4): e211-e213.
[5] SHINDE A, SEIFI A, DELRE S, et al.Daptomycin-induced pulmonary infiltrates with eosinophilia[J]. J Infect, 2009, 58(2): 173-174.
[6] DOAN TL, DEPETRILLO J, SINGER C.Daptomycin-induced eosinophilia without pulmonary involvement[J]. Am J Health Syst Pharm, 2010, 67(24): 2107-2109.
[7] LAL Y, ASSIMACOPOULOS AP.Two cases of daptomycin-induced eosinophilic pneumonia and chronic pneumonitis[J]. Clin Infect Dis, 2010, 50(5): 737-740.
[8] MILLER BA, GRAY A, LEBLANC TW, et al.Acute eosinophilic pneumonia secondary to daptomycin: a report of three cases[J]. Clin Infect Dis, 2010, 50(11): e63-e68.
[9] KALOGEROPOULOS AS, TSIODRAS S, LOVERDOS D, et al.Eosinophilic pneumonia associated with daptomycin: a case report and a review of the literature[J]. J Med Case Rep, 2011, 5: 13.
[10] RETHER C, CONEN A, GROSSENBACHER M, et al.A rare cause of pulmonary infiltrates one should be aware of: a case of daptomycin-induced acute eosinophilic pneumonia[J]. Infection, 2011, 39(6): 583-585.
[11] KIM PW, SORBELLO AF, WASSEL RT, et al.Eosinophilic pneumonia in patients treated with daptomycin: review of the literature and US FDA adverse event reporting system reports[J]. Drug Saf, 2012, 35(6): 447-457.
[12] PHILLIPS J, CARDILE AP, PATTERSON TF, et al.Daptomycin-induced acute eosinophilic pneumonia: analysis of the current data and illustrative case reports[J]. Scand J Infect Dis, 2013, 45(10): 804-808.
[13] PATEL JJ, ANTONY A, HERRERA M, et al.Daptomycin-induced acute eosinophilic pneumonia[J]. WMJ, 2014, 113(5): 199-201.
[14] YAMAMOTO K, HAYAKAWA K, OHMAGARI N.Daptomycin-induced pneumonitis in a patient with chronic obstructive pulmonary disease (COPD)[J]. Intern Med, 2014, 53(21): 2559-2560.
[15] YUSUF E, PERROTTET N, ORASCH C, et al.Daptomycin-associated eosinophilic pneumonia in two patients with prosthetic joint infection[J]. Surg Infect (Larchmt), 2014,15(6): 834-837.
[16] FISHER LH, CHOI J, BRICKER RS, et al.Photo quiz. Daptomycin-induced eosinophilic pneumonia[J]. Clin Infect Dis, 2015, 61(6): 978-1027.
[17] CHIU SY, FAUST AC, DAND HM.Daptomycin-induced eosinophilic pneumonia treated with intravenous corticosteroids[J]. J Pharm Pract, 2015, 28(3): 275-279.
[18] HAGIYA H, HASEGAWA K, ASANO K, et al.Myopathy and eosinophilic pneumonia coincidentally induced by treatment with daptomycin[J]. Intern Med, 2015, 54(5): 525-529.
[19] ROUX S, FERRY T, CHIDIAC C, et al.Daptomycin-induced eosinophilic pneumonia[J]. Int J Infect Dis, 2015, 37: 95-96.
[20] AKCAER M, KARAKAS A, TOK D, et al.Eosinophilic pneumonia: Daptomycin-induced lung complication[J]. Med Mal Infect, 2016, 46(3): 166-168.
[21] HATIPOGLU M, MEMIS A, TURHAN V, et al.Possible daptomycin-induced acute eosinophilic pneumonia in a patient with diabetic foot infection[J]. Int J Antimicrob Agents, 2016, 47(5): 414-415.
[22] HIRAI J, HAGIHARA M, HARANAGA S, et al.Eosinophilic pneumonia caused by daptomycin: six cases from two institutions and a review of the literature[J]. J Infect Chemother, 2017, 23(4): 245-249.
[23] ZACCARINI CG, DONG X.Poster 53 daptomycin-induced acute eosinophilic pneumonia in a patient receiving rehabilitation post prosthetic joint infection: a case report[J]. PMR, 2016, 8(9S): S178.
[24] RACHID M, AHMAD K, SAUNDERS-KURBAN M, et al.Daptomycin-induced acute eosinophilic pneumonia: late onset and quick recovery[J]. Case Rep Pulmonol, 2017, 2017: 8525789.
[25] HIGASHI Y, NAKAMURA S, TSUJI Y, et al.Daptomycin-induced eosinophilic pneumonia and a review of the published literature[J]. Intern Med, 2018, 57(2): 253-258.
[26] KUMAR S, ACOSTA-SANCHEZ I, RAJAGOPALAN N.Daptomycin- induced acute eosinophilic pneumonia[J]. Cureus, 2018, 10(6): e2899.
[27] RARU Y, ZEID F, BROWNING S, et al.Two patients with daptomycin induced eosinophilic pneumonia with different present-ations and treatment[J]. Respir Med Case Rep, 2017(23): 29-32.
[28] ABELENDA AG, MONTES RI, MARTÍN TJ, et al. Daptomycin eosinophilic pneumonia: an adverse effect to be aware of[J]. Rev Esp Quimioter, 2018, 31(3): 282-284.
[29] BASNET S, TACHAMO N, DHITAL R, et al.Daptomycin associated eosinophilic pneumonia: case report and differential diagnoses[J]. J Community Hosp Intern Med Perspect, 2018, 8(3): 152-155.
[30] RAZA A, ARSLAN A, ATIQ MU, et al.Unexpected outcome of daptomycin-induced eosinophilic pneumonia: rarity within a rarity[J]. Cureus, 2019, 11(12): e6271.
[31] STORANDT MH, MATTA A.Acute eosinophilic pneumonia: a rare complication of daptomycin therapy[J]. Cureus, 2020,12(1): e6803.
[32] OHNISHI H, ABE M, YOKOYAMA A, et al.Clarithromycin-induced eosinophilic pneumonia[J]. Intern Med, 2004, 43(3): 231-235.
[33] KLERKX S, PAT K, WUYTS W.Minocycline induced eosinophilic pneumonia: case report and review of literature[J]. Acta Clin Belg, 2009, 64(4): 349-354.
[34] PÉREZ-CASTRILLÓN JL, JIMÉNEZ-GARCÍA R, MARTÍN-ESCUDERO JC, et al. Roxithromycin-induced eosinophilic pneumonia[J]. Ann Pharmacother, 2002, 36(11): 1808-1809.
[35] ARBEIT RD, MAKI D, TALLY FP, et al.The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections[J]. Clin Infect Dis, 2004, 38(12): 1673-1681.
[36] ALLEN JN.Drug-induced eosinophilic lung disease[J]. Clin Chest Med, 2004, 25(1):77-88.
[37] KUO LC, LIN PC, WANG KF, et al.Successful treatment of gefitinib-induced acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review[J]. Med Oncol, 2011, 28(1): 79-82.

达托霉素致嗜酸粒细胞性肺炎的文献分析

Literature review of eosinophilic pneumonia induced by daptomycin

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.